PathAI Press & Releases

PathAI Appoints Biopharma Executive and Digital Pathology Leader Michael Montalto, Ph.D., as Chief Scientific Officer
Former VP of Translational Sciences at Bristol-Myers Squibb joins PathAI Executive Team

PathAI and Gilead Show AI-Powered Pathology Research Models Accurately Interpret Liver Histology in Patients with NASH at AASLD 2019
Machine learning-based analyses of phase 3 trial provide quantitative assessments of liver histology and highlight heterogeneity of pathology in NASH

PathAI and Bristol-Myers Squibb to Showcase Results From First AI-Powered Analysis of PD-L1 Expression Across Three Phase 3 Trials at SITC 2019
AI-based approaches accurately quantified PD-L1 expression on tumor and immune cells and similarly predicted patient response compared to manual assessment

PathAI Announces Strategic Investment from Merck Global Health Innovation Fund and Bristol-Myers Squibb to complete $75M Series B Funding
Backing by leading immuno-oncology companies underscores the broad potential for digital pathology and strength of PathAI

PathAI Announces Strategic Investment from LabCorp
Growing Relationship Between PathAI and LabCorp Will Help Advance the Clinical Development of Artificial Intelligence for Use with Digital Pathology

PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst
Computational Pathology Leader Plans to Accelerate Industry Impact

PathAI Earns ISO 27001 Security Certification
Digital Pathology Leader Elevates Privacy and Security Standards.

PathAI Earns Major Quality Certification, Expands Executive Team with Regulatory Expertise
Digital Pathology Leader paves way to regulated medical devices to help treat cancer